We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.79% | 2.85 | 2.80 | 2.90 | 2.875 | 2.80 | 2.80 | 150,500 | 09:00:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.17 | 135.84M |
TIDMAGY
RNS Number : 8138V
Allergy Therapeutics PLC
07 November 2017
The announcement released by Allergy Therapeutics plc entitled "Director/ PDMR Shareholding" on 7 November 2017 at 11:54 incorrectly stated the exercise price as GBP0.0001 per share. The correct exercise price is GBP0.001. All other figures remain unchanged. The correct figure is included in the reissued announcement below:
07 November 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Grant of Options under Long Term Incentive Plan
Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that certain performance conditions attaching to provisional awards ("Awards") made pursuant to the Company's Long Term Incentive Plan ("LTIP") for the three years ended 30 June 2017, details of which were announced on 5 November 2014, have been met. Consequently, Allergy Therapeutics has today granted to certain employees of the Company, including a PDMR, low cost options ("Options") over the Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in replacement for the Awards made under the LTIP. Details of the grant of Options to the PDMR are as follows:
Director Number of Total number Total remaining Ordinary of Ordinary number of Ordinary Shares over Shares over Shares provisionally which Options which Options awarded under granted granted LTIPs Manuel Llobet, Chief Executive Officer 626,399 626,399 1,690,000
The Options have been granted in accordance with the LTIP rules with an exercise price of GBP0.001 per share, and can be exercised between 07 November 2017 and 06 November 2027.
Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated --- ------------------------------------------------------------ a) Name Manuel Llobet --- ----------------- ----------------------------------------- 2 Reason for the notification Grant of Options --- ------------------------------------------------------------ a) Position/status Chief Executive Officer --- ----------------- ----------------------------------------- b) Initial Initial notification notification /Amendment --- ----------------- ----------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ------------------------------------------------------------ a) Name ALLERGY THERAPEUTICS PLC --- ----------------- ----------------------------------------- b) LEI 213800PQ7AHK7KGVOE23 --- ----------------- ----------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ------------------------------------------------------------ a) Description Options over Ordinary Shares of GBP0.001 of the each financial instrument, type of instrument GB00B02LCQ05 Identification code --- ----------------- ----------------------------------------- b) Nature Grant of Options of the transaction --- ----------------- ----------------------------------------- c) Price(s) Exercise Volume and volume(s) Price ---------- -------- GBP0.001 626,399 ---------- -------- --- ----------------- ----------------------------------------- d) Aggregated information - Aggregated volume 626,399 Options - Price GBP0.001 --- ----------------- ----------------------------------------- e) Date of 07 November 2017 the transaction --- ----------------- ----------------------------------------- f) Place of London Stock Exchange, AIM the transaction --- ----------------- -----------------------------------------
This announcement contains insider information for the purposes of Article 7 of Regulatory (EU) No596/2014.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBDBDBRUGBGRR
(END) Dow Jones Newswires
November 07, 2017 07:59 ET (12:59 GMT)
1 Year Allergy Therapeutics Chart |
1 Month Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions